ArticleWorld journal of urology2018
Immune phenotype of peripheral blood mononuclear cells in patients with high-risk non-muscle invasive bladder cancer.
Article in World journal of urology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 21 citations in OpenAlex.
- Single-cell analysis reveals potential therapeutic markers of peripheral blood mononuclear cells from bladder cancer patients.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2025Article
- Bladder cancer immune-related markers: diagnosis, surveillance, and prognosis.Frontiers in immunology · 2024Review
- The effects of aging, sex, and tumor burden on the peripheral blood immune cell profile and absolute counts.Journal of Cancer · 2024Article
- Tumour microenvironment as a predictive factor for immunotherapy in non-muscle-invasive bladder cancer.Cancer immunology, immunotherapy : CII · 2023Review
- TIM-3 and TIGIT are possible immune checkpoint targets in patients with bladder cancer.Urologic oncology · 2022Review
- Immune checkpoint expression on peripheral cytotoxic lymphocytes in cervical cancer patients: moving beyond the PD-1/PD-L1 axis.Clinical and experimental immunology · 2021Article
- Detection of Immune Checkpoint Receptors - A Current Challenge in Clinical Flow Cytometry.Frontiers in immunology · 2021Review
- Harnessing Natural Killer Cell Function for Genitourinary Cancers.The Urologic clinics of North America · 2020Review
- The Rise of NK Cell Checkpoints as Promising Therapeutic Targets in Cancer Immunotherapy.Frontiers in immunology · 2019Review
- Immunotherapy for bladder cancer: the fight is on.World journal of urology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
purposeTo explore the immune phenotype of peripheral blood mononuclear cells (PBMC) in patients with high-risk non-muscle invasive bladder cancer (NMIBC).
methodsWe prospectively collected blood samples from patients with high-risk NMIBC treated at our institution. PBMC were analyzed by flow cytometry to determine the frequency of T cells and NK cells and the expression of immunoregulatory molecules (Tim-3, TIGIT and PD-1). PBMC from healthy donors (HD) were included for comparison, and associations with response to BCG were investigated.
resultsA total of 38 patients were included, 19 BCG responders and 19 BCG refractory. Compared to 16 PBMC from HD, the frequency of total NK cells was significantly higher in patients with NMIBC [15.2% (IQR: 11.4, 22.2) vs. 5.72% (IQR: 4.84, 9.79); p = 0.05], whereas the frequency of T cells was not statistically different. Both Tim-3 and TIGIT expressions were significantly higher in NMIBC compared to HD, particularly in NK cells [13.8% (11.0; 22.4) vs. 5.56% (4.20; 10.2) and 34.9% (18.9; 53.5) vs. 1.82% (0.63; 5.16), respectively; p < 0.001]. Overall, the expression of PD-1 in all cell types was low in both NMIBC patients and HD. The immune phenotype was not significantly different before and after initiation of BCG. However, the proportion of CD8
conclusionThe immune phenotype of PBMC from patients with high-risk NMIBC was significantly different from HD, regardless of the presence of disease or the initiation of BCG. Peripheral CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.